Improving Human Life by Advancing the Field of Transplantation
Timely Topics in Transplantation
The American Society of Transplantation is pleased to present the Timely Topics in Transplantation On Demand Learning Resources, a series of webcasts available for viewing 24/7. The webcasts were recorded in the fall of 2011, with the exception of "ATC Highlights: Basic and Translational Science", which is a rebroadcast of a presentation given at the American Transplant Congress in May 2011. Each webcast is approximately 45-60 minutes long.
The 2011 T3 series was made possible in part by support from Astellas and Genzyme.
Registration Fees
The T3 series is available free of charge to AST members; simply log in above to view the webcasts.
Non-members may purchase access to any of the webcasts for a fee of $75 each; click on any of the available webcasts below to begin the purchase process.
Continuing education credit can be purchased for a fee of $25 for members and $35 for non-members (per webcast). For non-members, a "Purchase CME" button will appear only after you have purchased a webcast.
ATC Highlights: Liver and Cardiothoracic Transplantation
Kimberly Brown, MD (Liver) • Henry Ford Hospital
Josef Stehlik, MD, MPH (Cardiothoracic) • University of Utah School of Medicine
This program focuses on highlights from the 2011 American Transplant Congress in the areas of liver transplantation and cardiothoracic transplantation.
After participating in this activity, you will be able to:
- Summarize the recent advances in liver transplantation
-
Discuss:
- the impact of IL28B genetic variants on transplant outcomes in hepatitis C,
- the impact of protease inhibitors for hepatitis C on calcineurin drug exposure,
- the optimal timing for conversion from a CNI to Sirolimus in patients with renal insufficiency following liver transplantation; and
- the safety and efficacy of single agent treatment of patients with hepatitis B long term following liver transplantation.
- Articulate recent developments in the field of thoracic transplantation.
-
Discuss and determine the relevance of the following to his/her clinical practice:
- new approaches to the diagnosis and treatment of antibody-mediated rejection,
- novel biomarkers of cardiac allograft vasculopathy,
- implications of high risk donor for outcome after heart transplant; and
- the current state of mechanical circulatory support.
ATC Highlights: Kidney Transplantation
Emilio Poggio, MD • Cleveland Clinic
This program focuses on highlights from the American Transplant Congress in the area of kidney transplantation.
After participating in this activity, you will be able to:
- Discuss novel immunosuppressive drugs and/or regimens targeting T cells
- Describe ongoing efforts to develop tolerogenic protocols
- Review the results of registry data concerning the outcomes of kidney allografts in the setting of pancreas transplantation.
ATC Highlights: Basic and Translational Science
Roslyn Mannon, MD • University of Alabama at Birmingham
This program focuses on highlights from the American Transplant Congress in the area of basic and translational science. The talk was originally presented at the ATC in May 2011 in Philadelphia.
After participating in this activity, you will be able to:
- Define the mechanisms of immunologic injury in solid organ grafts.
- Identify new pathways in immune cell regulation and function.
- Describe novel pathways that may be clinically approached to limit immune mediated injury
Infectious Disease
Donor Derived Infections and Selection of OPTN-defined Increased Risk Donors
Michael Ison, MD • Northwestern University
Infectious Complications in Transplant Tourists
Camille Kotton, MD • Massachusetts General Hospital
Dr. Ison will review current recommendations for testing deceased donors, as well as the feasibility of expanding the deceased donor pool with OPTN-defined increased risk donors. Dr. Kotton will review the literature related to this subject and provide recommendations for evaluation of transplant tourists, who are at particular risk for infectious complications.
After participating in this activity, you will be able to:
- Discuss the epidemiology of donor-derived infections
- Compare the current and proposed definitions of increased risk donors
- Identify the infectious disease risks associated with transplant tourism including: donor derived infections (both organ and transfusion related), reactivation of latent infections, and de novo acquisition of geographic and nosocomial infections
Kidney Transplantation
Living Donor Transplantation: What Do We Know about Donor Outcomes?
Arthur Matas, MD • University of Minnesota
Why Are We Discarding So Many Deceased Kidneys in the United States?
Kevin O'Connor • Life Center Northwest
Dr. Matas will review recent evidence regarding the safety of living kidney donation, identify areas where additional information is needed, and highlight the most efficient strategies to obtain needed information. Mr. O’Connor will review efforts to increase deceased organ donation, and specifically the discard of deceased donor kidneys in the United States. International comparisons and examination of the factors contributing to discard will be reviewed.
After participating in this activity, you will be able to:
- Explain what is known about the risks after living kidney donation
- Define the limitations of the data on long-term follow-up after uni-nephrectomy
- Describe the current state of organ donation from deceased donors in the US, including changes over time in donor sub-types
- Identify factors associated with the trend towards decreased utilization of deceased donor kidneys, and strategies employed in Europe to maximize kidney utilization
Basic and Translational Science
Proteomics, Genomics and Immune Monitoring in Clinical Transplantation: How Can They Improve Outcomes
Bernd Schroppel, MD • Mount Sinai School of Medicine
Pancreatic Islet Cell Transplant...Where Are We Now?
A.M. James Shapiro, MD, PhD • University of Alberta
Coming soon!
Dr. Schroppel will critically review the status and clinical applicability of new methods of monitoring allograft health. Dr. Shapiro will evaluate the current status of Islet transplantation and provide perspective on the use of Islets versus solid pancreas transplantation.
After participating in this activity, you will be able to:
- Describe the methods of biomarker discovery and the phases of biomarker development
- Describe the tools available of monitoring allograft health and their potential to guide clinical decision making
- State the current progress and challenges in clinical islet transplantation
- Outline the next steps that will help facilitate transition of islet transplantation from research to routine clinical care for patients with unstable or complicated forms of Type 1 diabetes
Featured Event
What's New
